Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8301473 | 0.82 | CYP2C19 (0.40) | KCNN4CYP2C19HIF1ACHRM2CHRM1 | |
| SCHEMBL895242 | 0.80 | KCNN4 (0.36) | LMNAKCNN4MAPK1CYP2C19HIF1A | |
| SCHEMBL9371117 | 0.79 | EBP (0.39) | LMNAALDH1A1CES1 | |
| SCHEMBL23633166 | 0.78 | CYP1A2 (0.44) | LMNAMAPK1CYP2C19HIF1ATAAR1 | |
| SCHEMBL4675618 | 0.78 | MAPK1 (0.39) | KCNN4MAPK1CYP2C19HIF1ACHRM2 | |
| SCHEMBL11112464 | 0.77 | TSHR (0.37) | LMNAKCNN4MAPK1CYP2C19HIF1A | |
| SCHEMBL9207734 | 0.77 | KCNN4 (0.36) | LMNAKCNN4MAPK1CYP2C19HIF1A | |
| SCHEMBL10389019 | 0.77 | OPRM1 (0.50) | LMNACHRM2TAAR1ALDH1A1KDM4E | |
| SCHEMBL7764290 | 0.76 | KCNN4 (0.43) | LMNAKCNN4MAPK1CYP2C19HIF1A | |
| SCHEMBL29280866 | 0.76 | MAPK1 (0.48) | LMNAKCNN4MAPK1TAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| US-20240190897-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2024-06-13 | — | — | US | disclosed |
| US-11905301-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | CLARITY PHARMACEUTICALS LTD. (AU) | 2024-02-20 | — | — | US | disclosed |
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | Clarity Pharmaceuticals Ltd (AU) | 2024-02-15 | — | — | US | disclosed |
| EP-0202047-A1 | Pyrazolidinium ylides | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| US-3944590-A | ALKYL PHENYL CARBONATES | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | LMNA 2067/4885KCNN4 3812/4885MAPK1 2079/4885 |
| US-20240050600-A1 | Radiopharmaceuticals, uses thereof, and methods for the production thereof | GRPR, OGFR, GHRHR | LMNA 3208/4885KCNN4 4792/4885MAPK1 4461/4885 |
| US-11905301-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | NCL, NUDC, C3AR1 | LMNA 4611/4885KCNN4 4207/4885MAPK1 4380/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | LMNA 2144/4885KCNN4 3870/4885MAPK1 3711/4885 |
| US-20240190897-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | NCL, NUDC, C3AR1 | LMNA 4611/4885KCNN4 4207/4885MAPK1 4380/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | LMNA 2308/4885KCNN4 2388/4885MAPK1 1871/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | LMNA 1436/4885KCNN4 3179/4885MAPK1 3455/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | LMNA 1608/4885KCNN4 3232/4885MAPK1 2437/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | LMNA 2454/4885KCNN4 3053/4885MAPK1 3638/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | LMNA 2067/4885KCNN4 3812/4885MAPK1 2079/4885 |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | PSEN2, PSEN1, CHAT | LMNA 1737/4885KCNN4 2884/4885MAPK1 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.